新产业(300832) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥532,371,365.53, representing an increase of 84.37% compared to ¥288,752,653.30 in the same period last year[4] - Net profit attributable to shareholders was ¥168,144,761.01, up 51.82% from ¥110,749,641.17 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥144,437,086.36, reflecting a 50.17% increase from ¥96,184,723.10 in the previous year[4] - Basic and diluted earnings per share were both ¥0.4078, marking a 36.39% increase from ¥0.2990 in the previous year[4] - Operating profit for Q1 2021 was ¥203,235,312.87, up 60% from ¥127,050,662.79 in the same period last year[36] - The net profit from continuing operations for Q1 2021 was ¥168,034,342.26, an increase from ¥111,331,938.70 in the same period last year, representing a growth of approximately 50.8%[39] Cash Flow - The net cash flow from operating activities reached ¥118,803,772.88, a significant increase of 346.94% compared to ¥26,581,327.43 in the same period last year[4] - Cash inflow from operating activities totaled ¥526,458,939.65, compared to ¥318,898,147.53 in the previous year, indicating a year-over-year increase of about 65.1%[41] - The net cash flow from investment activities was -¥314,681,230.06, an improvement from -¥571,524,610.27 in the same quarter last year, reflecting a reduction in losses[44] - Cash and cash equivalents at the end of the period were ¥868,885,769.24, down from ¥1,439,052,474.99 at the end of the previous year, a decrease of approximately 39.5%[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,502,710,368.21, an increase of 3.71% from ¥5,305,693,720.85 at the end of the previous year[4] - Total liabilities decreased to ¥459,646,418.07 from ¥501,485,824.52, a reduction of approximately 8.3%[30] - The company's total current assets reached CNY 4,273,035,019.53, up from CNY 4,124,924,367.78, indicating an increase of about 3.6%[74] - The company's equity attributable to shareholders increased to CNY 5,043,063,950.14 from CNY 4,804,207,896.33, reflecting a growth of approximately 5%[77] Research and Development - Research and development expenses increased by 45.87% to CNY 40,254,361.51, driven by increased investment in R&D during the reporting period[14] - Research and development expenses for Q1 2021 were ¥40,254,361.51, an increase of 46% from ¥27,596,275.65 in Q1 2020[35] Government Support and Subsidies - The company received government subsidies amounting to ¥9,959,220.45 during the reporting period[5] - The company received tax refunds amounting to ¥6,830,741.36, compared to ¥5,478,780.62 in the previous year, which is an increase of about 24.6%[41] Shareholder Information - The top ten shareholders held a combined 70.27% of the company's shares, with the largest shareholder owning 26.95%[7] - The top shareholder, Tibet New Industry Investment Management Co., Ltd., held 26.95% of the shares, with a total of 111,146,000 shares[53] Investment Activities - The company has committed to various investment projects, with a total of CNY 120,251,160 raised, of which CNY 72,275,030 has been utilized, indicating a progress rate of 60.14%[21] - The company plans to utilize unallocated fundraising for the "New Industry Biomedical Research and Development Building" project after terminating the unused portion of the "New Industry Biomedical Overseas Expansion Project"[22] Cost Management - The company has implemented strict cost control measures during project execution, resulting in significant savings and a remaining balance of RMB 21.93 million for the "New Industry Biomedical Research Production Base Phase II" project[22] - The company reported a significant decrease in financial expenses by 84.01%, attributed to changes in exchange gains and losses[60]